PMID- 33003194
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20240329
IS  - 1477-4054 (Electronic)
IS  - 1467-5463 (Print)
IS  - 1467-5463 (Linking)
VI  - 22
IP  - 2
DP  - 2021 Mar 22
TI  - Adverse events associated with potential drugs for COVID-19: a case study from 
      real-world data.
PG  - 1232-1238
LID - 10.1093/bib/bbaa234 [doi]
LID - bbaa234
AB  - The coronavirus disease 2019 (COVID-19) has resulted as a global pandemic. The 
      World Health Organization announced the most promising drugs in SOLIDARITY for 
      the global trial, and several other drugs are under investigation through ongoing 
      clinical trials to prove the effectiveness and safety of potential therapeutics. 
      Here, we depicted the safety profile of these drugs and investigated their 
      associated adverse events (AEs). We observed the associated AEs in different 
      organs/systems, especially in skin and subcutaneous tissue, immune system and 
      musculoskeletal and connective tissue. Furthermore, we observed strong bias of 
      AEs in different groups of sex and age. Our study provides knowledge of the 
      toxicity of potential COVID-19 drugs. While these drugs hold promise to fight the 
      global pandemic, healthcare providers should pay attention to AEs to maximize the 
      treatment benefit while minimizing toxicity.
CI  - (c) The Author(s) 2020. Published by Oxford University Press. All rights reserved. 
      For Permissions, please email: journals.permissions@oup.com.
FAU - Jing, Ying
AU  - Jing Y
AD  - Department of Biochemistry and Molecular Biology, The University of Texas Health 
      Science Center at Houston McGovern Medical School, USA.
FAU - Diao, Lixia
AU  - Diao L
AD  - Department of Bioinformatics and Computational Biology, The University of Texas 
      MD Anderson Cancer Center, Houston, USA.
FAU - Han, Leng
AU  - Han L
AD  - Department of Biochemistry and Molecular Biology, The University of Texas Health 
      Science Center at Houston McGovern Medical School, USA.
LA  - eng
GR  - R21 AI150085/AI/NIAID NIH HHS/United States
GR  - R01 DK090570/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Brief Bioinform
JT  - Briefings in bioinformatics
JID - 100912837
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Adverse Drug Reaction Reporting Systems
MH  - Antiviral Agents/*adverse effects
MH  - COVID-19/virology
MH  - Female
MH  - Humans
MH  - Male
MH  - SARS-CoV-2/isolation & purification
MH  - *COVID-19 Drug Treatment
PMC - PMC7543289
OTO - NOTNLM
OT  - COVID-19
OT  - adverse events
OT  - real-world data
EDAT- 2020/10/02 06:00
MHDA- 2021/04/15 06:00
PMCR- 2020/10/08
CRDT- 2020/10/01 20:23
PHST- 2020/06/29 00:00 [received]
PHST- 2020/08/03 00:00 [revised]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/10/02 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2020/10/01 20:23 [entrez]
PHST- 2020/10/08 00:00 [pmc-release]
AID - 5917051 [pii]
AID - bbaa234 [pii]
AID - 10.1093/bib/bbaa234 [doi]
PST - ppublish
SO  - Brief Bioinform. 2021 Mar 22;22(2):1232-1238. doi: 10.1093/bib/bbaa234.